Cost-effectiveness of the use of low- and high-potency statins in people at low cardiovascular risk - Wikidata - wikimedia - TriplyDB

Cost-effectiveness of the use of low- and high-potency statins in people at low cardiovascular risk

Cost-effectiveness of the use of low- and high-potency statins in people at low cardiovascular risk

http://www.wikidata.org/entity/Q35551084

about

PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study Economic Evaluation of a Pharmacogenomics Test for Statin-Induced Myopathy in Cardiovascular High-Risk Patients Initiating a Statin.The efficacy and cost-effectiveness of statins in low-risk patients.Estimating the future burden of cardiovascular disease and the value of lipid and blood pressure control therapies in China.Hyperlipidemia as a risk factor for cardiovascular disease.Generic atorvastatin, the Belgian statin market and the cost-effectiveness of statin therapy.A systematic literature review of methods of incorporating mortality in cost-effectiveness analyses of lipid-lowering therapies.When is carotid angioplasty and stenting the cost-effective alternative for revascularization of symptomatic carotid stenosis? A Canadian health system perspective.

P2860

Q28083595-CD9F73D6-8927-4866-9494-1F4F0DE48797 Q28659664-BF9B7FE3-BABD-45C6-B126-4AF39A004F2C Q30490270-EFCC2CDE-43D4-4C43-9E21-0C9798C9DDE8 Q35551124-549D1036-8DF2-4DB6-BC78-689333249F57 Q36013827-B8AE67F7-A039-42C6-825F-7BCBF145C7A1 Q36609968-6FC8CB08-C154-4CB3-B1D4-FD3040A3037C Q38067640-22DDB8F1-E233-41D9-9E64-C28255271582 Q38754290-5FCEE6F2-F894-4819-9DEB-E9B5E34FF1BC Q43716111-40430B9F-A78B-4DEE-A102-57E8434A89EF

P2860

Cost-effectiveness of the use of low- and high-potency statins in people at low cardiovascular risk

http://www.wikidata.org/entity/Q35551084

description

2011 nî lūn-bûn

@nan

2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Cost-effectiveness of the use ...... ple at low cardiovascular risk

@ast

Cost-effectiveness of the use ...... ple at low cardiovascular risk

@en

type

label

Cost-effectiveness of the use ...... ple at low cardiovascular risk

@ast

Cost-effectiveness of the use ...... ple at low cardiovascular risk

@en

prefLabel

Cost-effectiveness of the use ...... ple at low cardiovascular risk

@ast

Cost-effectiveness of the use ...... ple at low cardiovascular risk

@en

P1433

Q35551084-0CBEDF3E-28BA-4085-A1AE-655320273A9A

P1476

Q35551084-59618C0C-2F9C-4433-92D1-7D33665A644A

P2093

Q35551084-1C4427A5-16D7-45B9-BC5C-450F442D2A1C

Q35551084-20D34DEC-9F48-4C1B-A9E6-694ADA174B4B

Q35551084-4CD16D29-2175-4578-B9F1-D479FC0EA002

Q35551084-67AD4AE8-306F-452F-BF51-8AF453747500

Q35551084-90BECA46-AC52-4314-9946-A5DC5845DC66

Q35551084-AE504C2A-855B-4478-8D92-0FA1D5964CCB

Q35551084-DFA9D733-D1EE-44EE-A567-64C5C69F1410

Q35551084-F899211E-09D3-41D8-8866-0DC8F31B18AC

P2860

Q35551084-04CA0F46-5838-4974-9972-7F696A22FDD6

Q35551084-0824479E-AF85-4CBC-B0A1-BA58A923A6CD

Q35551084-083F98DF-95F0-4975-93F6-5196827335FA

Q35551084-384D32BF-4001-4237-9305-80D450E41074

Q35551084-38C3D60E-6EB4-4BD1-BC55-7F29D2485F6E

Q35551084-3DD0BDAB-0C1E-4714-9087-27F790CC8022

Q35551084-3E235B85-A22C-4EF4-B560-A5082F5B7FCB

Q35551084-3E878C24-E4FD-47AB-B2F7-5145345AA7BC

Q35551084-4EB27FEA-0E6F-40BD-801B-0C4C80B61288

Q35551084-5D26F8E4-40A1-4913-AE1F-FC27CCC0E684

P304

Q35551084-2B17A885-ADB7-46A9-B29C-1C0DC24EB973

P31

Q35551084-DB84A486-7A5D-4400-9B40-BB149B401B4E

P356

Q35551084-C903237A-E833-48A0-A97D-85E61A15AC77

P407

Q35551084-73AA3952-BC39-4995-A718-BCB012D7FD01

P433

Q35551084-D2D3D00A-B311-49D3-9BA7-C896BCF61F35

P478

Q35551084-4B0B895E-4FBD-41F7-B68C-94B1E9C67F69

P50

Q35551084-1F547119-0488-4459-8DFE-7A1967DF7AC2

Q35551084-6DB8F28D-4008-4A7C-91B0-ADA89243F9F6

Q35551084-7E83C0AB-3800-44A6-9CB8-464AA3797AB6

Q35551084-AA95B12C-2149-4A05-92D4-01AA95E49438

P577

Q35551084-83E35377-C8B5-4A33-B589-0D0751DCEE4E

P5875

Q35551084-66A28E5C-E94D-448F-A5C6-B9EF32A7F157

P698

Q35551084-82BA6647-64F4-499F-8654-A5DDB224C9BE

P932

Q35551084-F9FC1604-FA95-4237-B3D9-4B2080B113EE

P356

P1433

Canadian Medical Association Journal

P1476

Cost-effectiveness of the use ...... ple at low cardiovascular risk

@en

P2093

Anita Lloyd

http://www.w3.org/2001/XMLSchema#string

Braden Manns

http://www.w3.org/2001/XMLSchema#string

Brenda Hemmelgarn

http://www.w3.org/2001/XMLSchema#string

Finlay A McAlister

http://www.w3.org/2001/XMLSchema#string

Fiona Clement

http://www.w3.org/2001/XMLSchema#string

Flora Au

http://www.w3.org/2001/XMLSchema#string

Jon Conly

http://www.w3.org/2001/XMLSchema#string

Scott Klarenbach

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy of statins for primary prevention in people at low cardiovascular risk: a meta-analysis

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants.

Cholesterol lowering, cardiovascular diseases, and the rosuvastatin-JUPITER controversy: a critical reappraisal.

Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.

Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial.

How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations.

Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people

A systematic review and economic evaluation of statins for the prevention of coronary events.

P304

E1180-8

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1503/CMAJ.101281

http://www.w3.org/2001/XMLSchema#string

P407

P433

16

http://www.w3.org/2001/XMLSchema#string

P478

183

http://www.w3.org/2001/XMLSchema#string

P50

Marcello Tonelli

Alberta Kidney Disease Network

P577

2011-10-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51709085

http://www.w3.org/2001/XMLSchema#string

P698

21989469

http://www.w3.org/2001/XMLSchema#string

P932

3216439

http://www.w3.org/2001/XMLSchema#string